SG11202106392RA - Combination of dextromethorphan and bupropion for treating depression - Google Patents
Combination of dextromethorphan and bupropion for treating depressionInfo
- Publication number
- SG11202106392RA SG11202106392RA SG11202106392RA SG11202106392RA SG11202106392RA SG 11202106392R A SG11202106392R A SG 11202106392RA SG 11202106392R A SG11202106392R A SG 11202106392RA SG 11202106392R A SG11202106392R A SG 11202106392RA SG 11202106392R A SG11202106392R A SG 11202106392RA
- Authority
- SG
- Singapore
- Prior art keywords
- dextromethorphan
- bupropion
- combination
- treating depression
- depression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962789451P | 2019-01-07 | 2019-01-07 | |
| US201962789431P | 2019-01-07 | 2019-01-07 | |
| US201962789446P | 2019-01-07 | 2019-01-07 | |
| US201962789488P | 2019-01-07 | 2019-01-07 | |
| PCT/US2020/012612 WO2020146412A1 (en) | 2019-01-07 | 2020-01-07 | Combination of dextromethorphan and bupropion for treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202106392RA true SG11202106392RA (en) | 2021-07-29 |
Family
ID=71521902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202106392RA SG11202106392RA (en) | 2019-01-07 | 2020-01-07 | Combination of dextromethorphan and bupropion for treating depression |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3908270A4 (en) |
| JP (1) | JP2022516361A (en) |
| KR (1) | KR20210110654A (en) |
| CN (4) | CN114712356A (en) |
| AU (2) | AU2020207261B2 (en) |
| BR (1) | BR112020025902A2 (en) |
| CA (2) | CA3223187A1 (en) |
| CL (1) | CL2021001810A1 (en) |
| CO (1) | CO2021008988A2 (en) |
| CR (1) | CR20210368A (en) |
| EC (1) | ECSP21051833A (en) |
| IL (1) | IL284663A (en) |
| MX (1) | MX2021008247A (en) |
| PE (1) | PE20212249A1 (en) |
| SG (1) | SG11202106392RA (en) |
| WO (1) | WO2020146412A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| JP2022516361A (en) * | 2019-01-07 | 2022-02-25 | アンテシップ バイオベンチャーズ トゥー エルエルシー | A combination of dextromethorphan and bupropion for the treatment of depression |
| EP4255433A4 (en) | 2020-12-01 | 2024-05-29 | Antecip Bioventures II LLC | Bupropion and dextromethrophan for reduction of suicide risk in depression patients |
| CN117693336A (en) * | 2021-07-21 | 2024-03-12 | 安泰赛普生物风投二代有限责任公司 | Treatment of depression |
| WO2023225511A1 (en) * | 2022-05-17 | 2023-11-23 | Antecip Bioventures Ii Llc | Treatment of depression |
| WO2024006853A1 (en) | 2022-06-30 | 2024-01-04 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11717518B1 (en) * | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009525343A (en) * | 2006-02-03 | 2009-07-09 | アバニール・ファーマシューティカルズ | Pharmaceutical composition comprising dextromethorphan and quinidine for the treatment of depression, anxiety and neurodegenerative diseases |
| JP2015533155A (en) * | 2012-10-11 | 2015-11-19 | アイエックス バイオファーマ リミテッド | Solid dosage form |
| EP2950799B1 (en) * | 2013-01-30 | 2019-12-04 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| US10512643B2 (en) * | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| NZ758432A (en) * | 2013-11-05 | 2021-07-30 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US9402843B2 (en) * | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
| RU2020116666A (en) * | 2014-09-14 | 2020-07-31 | Аванир Фармасьютикалз, Инк. | PHARMACEUTICAL COMPOSITIONS CONTAINING A DEXTROMETORPHANE COMPOUND AND QUINIDINE FOR THE TREATMENT OF EXCITATION IN DEMENSE |
| KR102524253B1 (en) * | 2014-11-21 | 2023-04-20 | 안테씨프 바이오벤쳐스 투 엘엘씨 | Methods of modulating drug plasma levels using erythrohydroxybupropion |
| JP2022516361A (en) * | 2019-01-07 | 2022-02-25 | アンテシップ バイオベンチャーズ トゥー エルエルシー | A combination of dextromethorphan and bupropion for the treatment of depression |
-
2020
- 2020-01-07 JP JP2021539451A patent/JP2022516361A/en active Pending
- 2020-01-07 BR BR112020025902-0A patent/BR112020025902A2/en unknown
- 2020-01-07 CA CA3223187A patent/CA3223187A1/en active Pending
- 2020-01-07 PE PE2021001138A patent/PE20212249A1/en unknown
- 2020-01-07 CN CN202210286580.XA patent/CN114712356A/en active Pending
- 2020-01-07 EP EP20737928.0A patent/EP3908270A4/en active Pending
- 2020-01-07 AU AU2020207261A patent/AU2020207261B2/en active Active
- 2020-01-07 CN CN202210286767.XA patent/CN114712357A/en active Pending
- 2020-01-07 CR CR20210368A patent/CR20210368A/en unknown
- 2020-01-07 CA CA3126062A patent/CA3126062C/en active Active
- 2020-01-07 KR KR1020217023974A patent/KR20210110654A/en not_active Application Discontinuation
- 2020-01-07 CN CN202080004041.1A patent/CN112437659B/en active Active
- 2020-01-07 MX MX2021008247A patent/MX2021008247A/en unknown
- 2020-01-07 CN CN202210286769.9A patent/CN114712358A/en active Pending
- 2020-01-07 SG SG11202106392RA patent/SG11202106392RA/en unknown
- 2020-01-07 WO PCT/US2020/012612 patent/WO2020146412A1/en unknown
-
2021
- 2021-07-06 IL IL284663A patent/IL284663A/en unknown
- 2021-07-07 CL CL2021001810A patent/CL2021001810A1/en unknown
- 2021-07-07 CO CONC2021/0008988A patent/CO2021008988A2/en unknown
- 2021-07-13 EC ECSENADI202151833A patent/ECSP21051833A/en unknown
-
2023
- 2023-07-06 AU AU2023204348A patent/AU2023204348A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025902A2 (en) | 2021-07-13 |
| PE20212249A1 (en) | 2021-11-24 |
| CN114712356A (en) | 2022-07-08 |
| EP3908270A4 (en) | 2022-02-16 |
| CL2021001810A1 (en) | 2022-03-04 |
| CA3223187A1 (en) | 2020-07-16 |
| AU2020207261B2 (en) | 2023-04-13 |
| JP2022516361A (en) | 2022-02-25 |
| ECSP21051833A (en) | 2021-11-18 |
| AU2023204348A1 (en) | 2023-07-27 |
| CA3126062C (en) | 2024-02-06 |
| WO2020146412A1 (en) | 2020-07-16 |
| IL284663A (en) | 2021-08-31 |
| AU2020207261A1 (en) | 2021-07-08 |
| CN112437659B (en) | 2022-04-12 |
| CO2021008988A2 (en) | 2021-09-09 |
| KR20210110654A (en) | 2021-09-08 |
| EP3908270A1 (en) | 2021-11-17 |
| CR20210368A (en) | 2021-12-10 |
| CN114712357A (en) | 2022-07-08 |
| CA3126062A1 (en) | 2020-07-16 |
| CN112437659A (en) | 2021-03-02 |
| CN114712358A (en) | 2022-07-08 |
| MX2021008247A (en) | 2021-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284663A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| IL268406A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| IL282600A (en) | Composition and method for treating the lungs | |
| IL283840A (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| ZA202207394B (en) | Compositions and methods for treating hemoglobinopathies | |
| IL275626A (en) | Surface treatment compositions and methods | |
| EP3858353A4 (en) | Pharmaceutical composition for preventing and treating nitm and pharmaceutical use thereof | |
| IL308221A (en) | Compositions and methods for the treatment of depression | |
| IL285886A (en) | Compositions and methods for treating laminopathies | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| IL290348A (en) | Surface treatment compositions and methods | |
| EP3801478A4 (en) | Methods and compositions for preventing or treating calciphylaxis | |
| EP4171606A4 (en) | Compositions and methods for the treatment of covid-19 | |
| IL280348A (en) | Surface treatment compositions and methods | |
| EP3829539A4 (en) | Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof | |
| IL285796A (en) | Methods and compositions for treating | |
| IL284565A (en) | Transdermal system for the delivery of abaloparatide and method of use | |
| IL280218A (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| ZA202007183B (en) | Compositions and methods for treating the eye | |
| EP3934655A4 (en) | Methods for the treatment of perimenopause and menopause | |
| PL3810128T3 (en) | Compositions for treating and/or preventing protein-aggregation diseases | |
| EP3999851A4 (en) | Compositions and methods for the treatment of tuberculosis | |
| EP3648756A4 (en) | Statin compositions and methods for use in treating synucleinopathies | |
| EP3816229A4 (en) | Silicone composition and fiber treatment agent using same | |
| EP3758692A4 (en) | Compositions and methods for treating pain |